FDA Panel Recommends Approval Of GRAIL's Galleri Multi-Cancer Early Detection Test

GRAIL Inc.'s (GRAL) Galleri multi-cancer early detection test has received a favorable vote from the FDA panel, making it one step closer to approval. The FDA's final decision on Galleri is expected in the coming months.